Look it's neither here nor there to me if you think it's a "bucket of crap". It's based on what I've learnt speaking to industry contacts who've had to deal with this before and know a lot more about the problems sparsentan had with FDA for that FSGS trial.
Ann: Dimerix presentation at Bioshares Biotech Summit, page-35
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.030(8.00%) |
Mkt cap ! $225.7M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 40.5¢ | 37.0¢ | $637.2K | 1.624M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 16500 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 169113 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |